ArticlePloS one2026
The impact of the COVID-19 pandemic on oral anticoagulation adherence in patients with atrial fibrillation managed in primary care: Results from the PRIME Registry.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral anticoagulants (OACs) are critical for preventing stroke in patients with atrial fibrillation (AF), yet adherence and persistence remain suboptimal, especially in primary care settings. The COVID-19 pandemic introduced new barriers to care that may have further disrupted medication use. This study aimed to examine the impact of the COVID-19 pandemic on OAC adherence and persistence among patients with nonvalvular AF managed in primary care practices.
methodsIn this retrospective cohort study, we used clinical records from the American Board of Family Medicine's (ABFM) PRIME Registry, for March 2017 through March 2023. We included 3,010 patients with documented AF and at least two OAC prescriptions prior to baseline. Persistence was assessed annually using a treatment anniversary method, and adherence was measured using the proportion of days covered (PDC), analyzed among persistent patients only. Interrupted time series and multivariable logistic regression models evaluated changes in quarterly persistence and factors associated with persistence and good adherence.
resultsPersistence declined sharply during the pandemic from 49.9% in 2018-2019 to 8.2% in the pandemic year-1. Adherence also dropped, with >95% PDC decreasing from 46.0% pre-pandemic to 17.7% in the pandemic year-2. Interrupted time series analysis showed a significant immediate drop in persistence. Compared to warfarin, NOAC use was associated with lower persistence in the pre-pandemic period, but higher persistence by the second year of the pandemic.
conclusionsThe COVID-19 pandemic was associated with sustained declines in OAC adherence and persistence among AF patients in primary care. Targeted interventions including telemedicine, home-based care, and attention to high-risk subgroups are essential to maintain continuity of care and improve adherence during public health crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.